` STTK (Shattuck Labs Inc) vs S&P 500 Comparison - Alpha Spread

STTK
vs
S&P 500

Over the past 12 months, STTK has underperformed S&P 500, delivering a return of -82% compared to the S&P 500's +13% growth.

Stocks Performance
STTK vs S&P 500

Loading
STTK
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
STTK vs S&P 500

Loading
STTK
S&P 500
Difference
www.alphaspread.com

Performance By Year
STTK vs S&P 500

Loading
STTK
S&P 500
Add Stock

Competitors Performance
Shattuck Labs Inc vs Peers

S&P 500
STTK
ABBV
AMGN
GILD
VRTX
Add Stock

Shattuck Labs Inc
Glance View

Market Cap
38.8m USD
Industry
Biotechnology

Shattuck Labs, Inc. engages in the research and development of Agonist Redirected Checkpoint (ARC) platform. The company is headquartered in Austin, Texas and currently employs 85 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of dual-sided fusion proteins. The firm has created an approach to immune modulation by designing biologics with structural characteristics. Compounds derived from its Agonist Redirected Checkpoint (ARC) platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the cluster of differentiation 47/signal regulatory protein alpha (CD47/SIRPa) checkpoint interaction to restore an anti-tumor immune response and to activate the cluster of differentiation 40 (CD40) costimulatory receptor to bolster an immune response. The firm's second product candidate, SL-279252, is designed to simultaneously inhibit the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction and activate the OX40 receptor.

STTK Intrinsic Value
1.1093 USD
Undervaluation 27%
Intrinsic Value
Price
Back to Top